EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib

Yan-Ou Yang iD, Yunlan Fang, Phillip Wang iD, Xiang Liu, Jay Getsy, Kevin Rockich

British Journal of Clinical Pharmacology · 2025

DOI: 10.1002/bcp.70372 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Yan-Ou Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Pharmacometrics, Incyte Corporation, Wilmington, Delaware, USA. Hauptthemen laut MEDLINE: Kidney Failure, Chronic, Protein Kinase Inhibitors, Renal Insufficiency, Liver Diseases. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Incyte Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Small‐molecule activin receptor‐like kinase‐2 inhibitor zilurgisertib (INCB000928) is under investigation in a pivotal trial for the treatment of fibrodysplasia ossificans progressiva (FOP), an ultrarare genetic condition. This analysis assessed effects of renal and hepatic impairment on zilurgisertib pharmacokinetics.

Methods

Two open‐label, parallel‐group studies were conducted. Participants with renal or hepatic impairment were matched with healthy controls and received a single 200‐mg dose of zilurgisertib; those with end‐stage renal disease (ESRD) received doses before and after haemodialysis. Plasma concentrations were quantified via validated assay; pharmacokinetic parameters were derived from non‐compartmental analysis. Geometric mean ratios (GMRs) and 90% confidence intervals (CIs) for C max , AUC 0‐t and AUC 0‐∞ were compared by ANOVA.

Results

Compared with matched controls, GMRs (90% CIs) for C max and AUC 0‐∞ were as follows: mild renal impairment, 0.92 (0.64–1.34) and 0.98 (0.77–1.24); moderate, 1.22 (0.92–1.63) and 1.64 (1.28–2.10); severe, 1.00 (0.74–1.35) and 1.70 (1.33–2.16), respectively. Among participants with ESRD, values were the following: before haemodialysis, 1.17 (0.91–1.49) and 1.47 (1.15–1.88); after, 1.32 (1.00–1.75) and 1.68 (1.29–2.19), respectively. Among participants with hepatic impairment, values were as follows: moderate, 1.06 (0.80–1.42) and 1.13 (0.93–1.38); severe: 1.36 (1.05–1.76) and 1.25 (1.06–1.48), respectively.

Conclusions

Zilurgisertib exposure was unchanged with mild renal or moderate hepatic impairment, but increased by 30%–70% with moderate or more severe renal impairment and by 25% with severe hepatic impairment. These findings, alongside the therapeutic index, to be defined by the ongoing pivotal FOP trial (NCT05090891), will guide dosing in these populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney Failure, ChronicProtein Kinase InhibitorsRenal InsufficiencyLiver DiseasesHumansMaleFemaleMiddle AgedAdultArea Under CurveRenal DialysisYoung AdultAgedCase-Control Studies

Stichwörter der Autor:innen

ALK2 inhibitorfibrodysplasia ossificans progressivahepatic impairmentpharmacokineticsrenal impairmentzilurgisertib

Substanzen

Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Pharmacology and Pharmacometrics, Incyte Corporation, Wilmington, Delaware, USA.
  • Department of Bioanalysis, Incyte Corporation, Wilmington, Delaware, USA.
  • Department of Early Development, Incyte Corporation, Wilmington, Delaware, USA.

ORCID-Profile: Yan-Ou Yang, Phillip Wang

Förderung

  • Incyte Corporation

Zitieren

APA

Yang, Y. O., Fang, Y., Wang, P., Liu, X., Getsy, J., & Rockich, K. (2025). Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70372

Vancouver

Yang YO, Fang Y, Wang P, Liu X, Getsy J, Rockich K. Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70372

BibTeX
@article{Yang2025,
  author = {Yang, Yan-Ou and Fang, Yunlan and Wang, Phillip and Liu, Xiang and Getsy, Jay and Rockich, Kevin},
  title = {Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/bcp.70372}
}
Kostenlos starten →